Bayer AG
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast age… Read more
Bayer AG (BAYZF) - Total Assets
Latest total assets as of December 2024: $110.85 Billion USD
Based on the latest financial reports, Bayer AG (BAYZF) holds total assets worth $110.85 Billion USD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bayer AG - Total Assets Trend (2004–2024)
This chart illustrates how Bayer AG’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bayer AG - Asset Composition Analysis
Current Asset Composition (December 2024)
Bayer AG's total assets of $110.85 Billion consist of 31.1% current assets and 68.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.6% |
| Accounts Receivable | $8.97 Billion | 8.1% |
| Inventory | $13.40 Billion | 12.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $22.11 Billion | 20.0% |
| Goodwill | $30.02 Billion | 27.1% |
Asset Composition Trend (2004–2024)
This chart illustrates how Bayer AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bayer AG's current assets represent 31.1% of total assets in 2024, a decrease from 52.2% in 2004.
- Cash Position: Cash and equivalents constituted 5.6% of total assets in 2024, down from 9.5% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, an increase from 15.0% in 2004.
- Asset Diversification: The largest asset category is goodwill at 27.1% of total assets.
Bayer AG Competitors by Total Assets
Key competitors of Bayer AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
Bayer AG - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Bayer AG generates 0.42x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Bayer AG is currently not profitable relative to its asset base.
Bayer AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.19 | 1.27 | 1.48 |
| Quick Ratio | 0.73 | 0.80 | 1.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.49 Billion | $ 8.10 Billion | $ 10.68 Billion |
Bayer AG - Advanced Valuation Insights
This section examines the relationship between Bayer AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.72 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -4.7% |
| Total Assets | $110.85 Billion |
| Market Capitalization | $21.61 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Bayer AG's assets below their book value (0.19 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Bayer AG's assets decreased by 4.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Bayer AG (2004–2024)
The table below shows the annual total assets of Bayer AG from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $110.85 Billion | -4.65% |
| 2023-12-31 | $116.26 Billion | -6.90% |
| 2022-12-31 | $124.88 Billion | +3.86% |
| 2021-12-31 | $120.24 Billion | +2.73% |
| 2020-12-31 | $117.05 Billion | -7.30% |
| 2019-12-31 | $126.26 Billion | -0.02% |
| 2018-12-31 | $126.28 Billion | +68.18% |
| 2017-12-31 | $75.09 Billion | -8.70% |
| 2016-12-31 | $82.24 Billion | +11.26% |
| 2015-12-31 | $73.92 Billion | -13.01% |
| 2014-12-31 | $84.97 Billion | +65.57% |
| 2013-12-31 | $51.32 Billion | -29.81% |
| 2006-12-31 | $73.12 Billion | +62.83% |
| 2005-12-31 | $44.90 Billion | -12.18% |
| 2004-12-31 | $51.13 Billion | -- |